RZLT vs. GYRE, MRVI, PAHC, ELVN, COLL, ZYME, NTLA, COGT, PHVS, and PSTX
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), Phibro Animal Health (PAHC), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Cogent Biosciences (COGT), Pharvaris (PHVS), and Poseida Therapeutics (PSTX). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs.
Gyre Therapeutics (NASDAQ:GYRE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
Rezolute has lower revenue, but higher earnings than Gyre Therapeutics.
In the previous week, Rezolute had 15 more articles in the media than Gyre Therapeutics. MarketBeat recorded 16 mentions for Rezolute and 1 mentions for Gyre Therapeutics. Rezolute's average media sentiment score of 1.01 beat Gyre Therapeutics' score of 0.49 indicating that Rezolute is being referred to more favorably in the news media.
Rezolute has a consensus price target of $24.38, suggesting a potential upside of 438.08%. Given Rezolute's stronger consensus rating and higher probable upside, analysts plainly believe Rezolute is more favorable than Gyre Therapeutics.
Gyre Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 18.4% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Rezolute received 72 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
Rezolute has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Rezolute's return on equity of -70.27% beat Gyre Therapeutics' return on equity.
Summary
Rezolute beats Gyre Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RZLT Stock Alerts